BB-1701
- Generic Name
- BB-1701
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- -
- Background
BB-1701 is a humanized IgG1 kappa monoclonal antibody (anti-HER2 antibody) conjugated to eribulin developed by Bliss Biopharmaceutical.
- Associated Conditions
- -
- Associated Therapies
- -
A Study of BB-1701 in Previously Treated Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive or HER2-low Unresectable or Metastatic Breast Cancer
- First Posted Date
- 2024-01-03
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 135
- Registration Number
- NCT06188559
- Locations
- 🇺🇸
Northwest Medical Specialties, Puyallup, Washington, United States
🇺🇸Cleveland Clinic - Fairview Hospital - Cancer Center (Moll Cancer Center), Cleveland, Ohio, United States
🇺🇸Cleveland Clinic - Hillcrest Hospital - Hillcrest Cancer Center, Cleveland, Ohio, United States
A First-in-human Study of Multiple Doses of BB-1701 in Subjects With Locally Advanced/Metastatic HER2 Expressing Solid Tumors
Phase 1
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2020-02-05
- Last Posted Date
- 2023-12-15
- Lead Sponsor
- Bliss Biopharmaceutical (Hangzhou) Co., Ltd
- Target Recruit Count
- 208
- Registration Number
- NCT04257110
- Locations
- 🇨🇳
Sir Run Run Shaw Hospital - Zhejiang University School of Medicine, Hangzhou, China
🇨🇳The First Affiliated Hospital of Zhejiang University, Hangzhou, China
🇨🇳Linyi Cancer Hospital, Linyi, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath